Before You Sell Consider this Article? Endocyte (ECYT)

Let’s consider Endocyte (ECYT) stock move that changed on Friday Dated AUGUST 31, 2018. 938045 shares changed at hands in last session versus to an average volume of 1218.8K shares. Endocyte stock ended at $19.72 by scoring 2.39%. It has 69.71M outstanding shares and 66.41M shares have been floated in market exchange. The stock institutional ownership included 85.50% while insider ownership remained 0.80%. The net percent change held by Institutional Investors has seen a change of 11.27% over last three month period. The net percent change kept by insiders has seen a change of -7.48% over last six month period.

Stock’s Price Fluctuations & Volatility:

The stock price registered volatility 7.26% in past week and volatility was at 5.36% over a last month. Historical volatility refers to the price fluctuations exhibited by the underlying asset (such as stock) over time. A security with high volatility has bigger fluctuations in price compared to a security with low volatility. The more quickly a price changes up and down, the more volatile it is. As such, volatility is often used as a measure of risk.

The stock’s Average True Range for 14 days was 1. ATR measures volatility, taking into account any gaps in the price movement. High ATR indicates increased volatility. A low ATR value indicates a series of periods with small ranges. Company’s beta coefficient stands at 0.23. Beta factors measures the amount of market risk associated with market trade. The stock has a RSI reading of 68.57.

Endocyte (ECYT) Stock’s Moving Average & Performance Analysis:

The stock showed weekly performance of 7.35% and it maintained for the month at 20.98%. Likewise the performance for the quarter was recorded as 48.27% and for the year it was 1350.00%. The stock showed 211.53% performance during last 6-months. The YTD performance remained at 360.75%. This stock traded upward toward its 52 week low with 1382.71% and -4.27% lower from its 52 week high price. The stock price is moving up from its 20 days moving average with 14.03% and it is trading up from 50 days moving average with 21.22%. The stock price is moving along positive drift from its 200 days moving average with 101.10%.

Endocyte (ECYT) Stock’s Ratio Analysis:

The Company was able to keep Return on assets (ROA) at -37.40% in the trailing twelve month. ROA shows that how profitable a company is relative to its total assets. ROA gives an idea as to how efficient management is at using its assets to generate earnings. Calculated by dividing a company’s annual earnings by its total assets, ROA is displayed as a percentage. The Company generated Return on equity (ROE) -38.90% over the last twelve months. ROE is a measure of a corporation’s profitability that reveals how much profit a company generates with the money shareholders have invested. Calculated as Net Income / Shareholder’s Equity.

Long Term Debt/Equity ratio was recorded at 0. This measures a company’s financial leverage calculated by dividing its long term debt by stockholders’ equity. It indicates what proportion of equity and debt the company is using to finance its assets. On the other side the debt to equity ratio is 0. Its current ratio is 28.3. Current Ratio is a liquidity ratio that measures a company’s ability to pay short-term obligations. Quick Ratio of 28.3 is an indicator of a company’s short-term liquidity. The quick ratio measures a company’s ability to meet its short-term obligations with its most liquid assets. The higher the quick ratio, the better the position of the company.

Mark Fife

Mark Fife

Mark Fife has an experience in Journalism and Content Writing, love writing stories full of efficient language and accurate content. He is a graduate of University of Sydney and has two years’ experience of Wall Street Investor. Mark covers Business category. His articles are published on Seeking Alpha, The Street, and The Motley Fool. Brianna has over 4 year experience as a news writer. Previously, he worked as a tech news reporter. Email Contact:

Leave a Reply

Your email address will not be published. Required fields are marked *